Results 91 to 100 of about 87,055 (280)
Currently, there are scarce data on how COVID-19 affects people with myasthenia gravis. Theoretically, there is a higher risk of experiencing severe manifestations of COVID-19 due to the common use of immunosuppressive drugs and potential respiratory ...
E. Aksoy, T. Oztutgan
semanticscholar +1 more source
A total of 95 ERT‐experienced adults with LOPD were randomized to switch to cipaglucosidase alfa + miglustat or remain on alglucosidase alfa treatment. After 52 weeks, patients remaining on alglucosidase alfa showed worsening or stability for most outcomes, whereas patients who switched to cipaglucosidase alfa + miglustat generally showed stability or ...
Hani Kushlaf+17 more
wiley +1 more source
About 5-10% of patients with myasthenia gravis concomitantly have other autoimmune diseases. However, the coexistence of myasthenia gravis and pernicious anemia is rare.
Kuo-Hsuan Chang+4 more
doaj +1 more source
Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare ...
Tuan Vu+9 more
doaj +1 more source
ABSTRACT Introduction/Aims Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a potentially disabling autoimmune neuropathy. Approximately 20% of patients are refractory to first‐line treatments necessitating second‐line options with limited evidence and potential adverse effects.
Shamim Miah+6 more
wiley +1 more source
ABSTRACT Introduction/Aims The Adverse Event Unit (AEU) is a patient and physician weighted unit that quantifies and compares adverse event (AE) burden among any neurologic treatments. A recent study demonstrated feasibility and preliminary validity of the AEU in myasthenia gravis (MG).
Michael K. Hehir+2 more
wiley +1 more source
Dental Care in Patients with Myasthenia Gravis
Myasthenia gravis is an autoimmune disease in the neuromuscular transmission, causing muscular weakness and fatique especially in the facial and pharyngeal muscles.
J. Piťha
doaj
MGBase: A Global, Observational Registry for Collaborative Research in Myasthenia Gravis
ABSTRACT Introduction/Aims Patient registries are valuable tools for outcomes research in rare diseases such as myasthenia gravis (MG). Existing MG registries are limited by factors including a lack of geographical scope. MGBase has been designed as a global, observational registry aimed at studying clinical practice outcomes in MG.
Katherine A. Buzzard+28 more
wiley +1 more source
Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody‐positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open‐label extension of REGAIN,
S. Muppidi+19 more
semanticscholar +1 more source
Abstract Respiratory acidosis and alkalosis are two of the four main acid‐base processes encountered in clinical practice. These two processes are tightly balanced by breathing. Identification and management of respiratory acid‐base disorders are important for clinicians, particularly when caring for patients with underlying pulmonary and neurological ...
Anne M. Tucker, Tami N. Johnson
wiley +1 more source